
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AP601
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : AP Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
Details : AP601 is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 10, 2025
Lead Product(s) : AP601
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : AP Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Radiprodil
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Recipient : GRIN Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Open-Label DDI Study of Radiprodil with Co-Administered Drugs
Details : Radiprodil is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Tuberous Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2025
Lead Product(s) : Radiprodil
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Recipient : GRIN Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Radiprodil
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Recipient : GRIN Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Radiprodil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberous Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2025
Lead Product(s) : Radiprodil
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Recipient : GRIN Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : iQ-007
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : iQure Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IQ-007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Resistant Epilepsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2025
Lead Product(s) : iQ-007
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : iQure Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : S-4321
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Seismic Therapeutic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-4321 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 14, 2025
Lead Product(s) : S-4321
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Seismic Therapeutic
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : S-1117
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Seismic Therapeutic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-1117 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
February 14, 2025
Lead Product(s) : S-1117
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Seismic Therapeutic
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PVT201
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Parvus Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PVT201 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Cirrhosis, Biliary.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : PVT201
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Parvus Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Kither Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KIT2014 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 26, 2024
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Kither Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SPG601
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Spinogenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of SPG601 in Adult Men With Fragile X Syndrome
Details : SPG601 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : SPG601
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Spinogenix
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Recipient : Oragenics
Deal Size : Undisclosed
Deal Type : Partnership
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
Details : The partnership aims to evaluate Oragenics' lead drug candidate, ONP-002, a NCE delivered through a unique intranasal device, for mild Traumatic Brain Injury.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 07, 2024
Lead Product(s) : ONP-002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Recipient : Oragenics
Deal Size : Undisclosed
Deal Type : Partnership
